Cargando…
Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis
BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidanc...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246921/ https://www.ncbi.nlm.nih.gov/pubmed/32996148 http://dx.doi.org/10.1111/all.14605 |
_version_ | 1783716412654616576 |
---|---|
author | Pelletier, Benjamin Perrin, Audrey Assoun, Noémie Plaquet, Camille Oreal, Nathalie Gaulme, Laetitia Bouzereau, Adeline Labernardière, Jean‐Louis Ligouis, Mélanie Dioszeghy, Vincent Wavrin, Sophie Matthews, Katie Porcheray, Fabrice Sampson, Hugh A. Hervé, Pierre‐Louis |
author_facet | Pelletier, Benjamin Perrin, Audrey Assoun, Noémie Plaquet, Camille Oreal, Nathalie Gaulme, Laetitia Bouzereau, Adeline Labernardière, Jean‐Louis Ligouis, Mélanie Dioszeghy, Vincent Wavrin, Sophie Matthews, Katie Porcheray, Fabrice Sampson, Hugh A. Hervé, Pierre‐Louis |
author_sort | Pelletier, Benjamin |
collection | PubMed |
description | BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. OBJECTIVE: We aimed to evaluate the capacity of EPIT to provide protection against cashew‐induced anaphylaxis in a relevant mouse model. METHODS: The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew‐sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast‐cell proteases (mMCP)‐1/7, were quantified. RESULTS: Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast‐cell reactivity as attested by the reduction of mMCP‐1/7 in plasma, suggesting that EPIT specifically decrease IgE‐mediated anaphylaxis. CONCLUSION: We demonstrate that EPIT markedly reduced IgE‐mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy. |
format | Online Article Text |
id | pubmed-8246921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82469212021-07-02 Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis Pelletier, Benjamin Perrin, Audrey Assoun, Noémie Plaquet, Camille Oreal, Nathalie Gaulme, Laetitia Bouzereau, Adeline Labernardière, Jean‐Louis Ligouis, Mélanie Dioszeghy, Vincent Wavrin, Sophie Matthews, Katie Porcheray, Fabrice Sampson, Hugh A. Hervé, Pierre‐Louis Allergy ORIGINAL ARTICLES BACKGROUND: The prevalence of tree nut allergy has increased worldwide, and cashew has become one of the most common food allergens. More critically, cashew allergy is frequently associated with severe anaphylaxis. Despite the high medical need, no approved treatment is available and strict avoidance and preparedness for prompt treatment of allergic reactions are considered dual standard of care. In the meantime, Phase III study results suggest investigational epicutaneous immunotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality of life for many peanut allergic children. OBJECTIVE: We aimed to evaluate the capacity of EPIT to provide protection against cashew‐induced anaphylaxis in a relevant mouse model. METHODS: The efficacy of EPIT was evaluated by applying patches containing cashew allergens to cashew‐sensitized mice. As negative control, sham mice received patches containing excipient. Following treatment, mice were challenged orally to cashew and anaphylactic symptoms, as well as plasmatic levels of mast‐cell proteases (mMCP)‐1/7, were quantified. RESULTS: Of 16 weeks of EPIT significantly protects against anaphylaxis by promoting a faster recovery of challenged mice. This protection was characterized by a significant reduction of temperature drop and clinical symptoms, 60 minutes after challenge. This was associated with a decrease in mast‐cell reactivity as attested by the reduction of mMCP‐1/7 in plasma, suggesting that EPIT specifically decrease IgE‐mediated anaphylaxis. CONCLUSION: We demonstrate that EPIT markedly reduced IgE‐mediated allergic reactions in a mouse model of cashew allergy, which suggests that EPIT may be a relevant approach to treating cashew allergy. John Wiley and Sons Inc. 2020-10-23 2021-04 /pmc/articles/PMC8246921/ /pubmed/32996148 http://dx.doi.org/10.1111/all.14605 Text en © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ORIGINAL ARTICLES Pelletier, Benjamin Perrin, Audrey Assoun, Noémie Plaquet, Camille Oreal, Nathalie Gaulme, Laetitia Bouzereau, Adeline Labernardière, Jean‐Louis Ligouis, Mélanie Dioszeghy, Vincent Wavrin, Sophie Matthews, Katie Porcheray, Fabrice Sampson, Hugh A. Hervé, Pierre‐Louis Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title | Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title_full | Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title_fullStr | Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title_full_unstemmed | Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title_short | Epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
title_sort | epicutaneous immunotherapy protects cashew‐sensitized mice from anaphylaxis |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246921/ https://www.ncbi.nlm.nih.gov/pubmed/32996148 http://dx.doi.org/10.1111/all.14605 |
work_keys_str_mv | AT pelletierbenjamin epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT perrinaudrey epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT assounnoemie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT plaquetcamille epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT orealnathalie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT gaulmelaetitia epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT bouzereauadeline epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT labernardierejeanlouis epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT ligouismelanie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT dioszeghyvincent epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT wavrinsophie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT matthewskatie epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT porcherayfabrice epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT sampsonhugha epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis AT hervepierrelouis epicutaneousimmunotherapyprotectscashewsensitizedmicefromanaphylaxis |